LMAT vs SRPT · P/E 35, rev $136.9M vs rev $1.13B
LeMaitre Vascular Inc (LMAT) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
LeMaitre Vascular Inc (LMAT) is a medical instruments & supplies company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported LMAT revenue for 2026-06-30 was $136.9M. Net income was $32.7M. LMAT currently screens at market cap $2.16B and trailing P/E 34.8.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
LMAT currently screens at market cap $2.16B and trailing P/E 34.8. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the LMAT and SRPT stock pages for the full models.
Not investment advice.